VLife Sciences Technologies Pvt. Ltd. (VLife) today announced that its customer NovaLead Pharma Pvt. Ltd. (NovaLead) has successfully filed an IND application with US FDA for Galnobax^®, a candidate to treat diabetic foot ulcers. Galnobax has been discovered exclusively using technology developed by and licensed from VLife.

NovaLead had earlier signed an agreement with VLife by which it was to exclusively use VLife’s technologies for its new chemical entities (NCE) and new indication programs. The agreement covered licensing of customized technologies from VLife and standard software suites such as VLifeMDS^®and QSARpro^® for a period of three years. Under this agreement VLife has developed and supports special technology products designed for NovaLead’s research goals.

About VLife Sciences Technologies Pvt. Ltd.
VLife Sciences Technologies Private Limited, Pune is a leading provider of licensed software and research solutions for discovery research projects in a variety of sectors. The software offers numerous unique and specialized features for applications in computer aided molecular discovery, bioinformatics, biotechnology and chemoinformatics. Technologies developed by VLife are unique, novel and offer advantages in terms of speed and accuracy thus leading to improved outcome from discovery research projects. VLife offers the VLifeMDS^® suite for a comprehensive approach to computer aided drug design and the QSARpro^® suite for advanced quantitative structure activity relationships analysis leading to new molecule design.

For more details please visit: www.vlifesciences.com or contact us at info@vlifesciences.com